
    
      A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter,
      laboratory classroom study. After Screening and Baseline evaluations, eligible subjects are
      enrolled in the study and entered the open-label phase, dose-optimization phase. TRI102 is
      taken once daily and subjects undergo dose optimization activities for 5 weeks.
    
  